Abstracts tagged "autoimmune diseases"

Abstract Number: LB04 • ACR Convergence 2025
Anti-CD20/BCMA Bispecific CAR-T Cell Therapy Promotes Immune Reset and Sustained Drug Free Remission in Refractory Autoimmune Diseases
Huihua Ding¹, Wensi Li², Yiwen Shen³, Chunyan Zhang⁴, Yan Ye³, Ran Wang³, Shaoying Yang³, Chunmei Wu³, Dai Dai³, Chengxiao Zheng², Yuan Qian², Xiaobing Luo⁵, Thule Trinh⁵, Judy Zhu², Jiaqi Huang⁵, Yong Hao³, Xiaoying Yao³, Zhenfen Ling⁶, Yihong Yao⁵ and Nan Shen¹, ¹Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ²Shanghai AbelZeta Ltd., Shanghai, China (People's Republic), ³Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁴Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China, ⁵AbelZeta Inc., Rockville, ⁶Shanghai General Hospital, Shanghai, China (People's Republic)
Background/Purpose: Refractory autoimmune diseases with progressive organ damage remain a major unmet medical need. C-CAR168 is an autologous anti-CD20/BCMA bispecific CAR-T therapy designed to simultaneously…
Abstract Number: LB10 • ACR Convergence 2025
Four-Year Safety and Efficacy of Deucravacitinib in Systemic Lupus Erythematosus: Results From a Phase 2 Program
Eric F. Morand¹, Cristina Arriens², Marilyn Pike³, Joan Merrill⁴, Victoria Werth⁵, Zahi Touma⁶, Razvan C. Ionitescu⁷, Masato Okada⁸, Ilias Kouris⁹, Yogita Kolekar¹⁰, Junyu Nie¹⁰, Venkat Renukuntla¹⁰, Thomas Wegman¹⁰ and Ronald van Vollenhoven¹¹, ¹Sub-Faculty of Clinical and Molecular Medicine, Monash University, Melbourne, Victoria, Australia, Melbourne, Victoria, Australia, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Rheumatology, MedPharm Consulting, Inc, Bethesda, ⁴Department of Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, ⁵University of Pennsylvania, Merion Station, Pennsylvania, ⁶University of Toronto, Toronto, Ontario, Canada, ⁷Medart Cliniq, Department of Rheumatology, Râmnicu Vâlcea, Romania, ⁸St. Luke's International Hospital, Tokyo, Japan, ⁹Eli Lilly and Company Global, Basingstoke, United Kingdom, ¹⁰Bristol Myers Squibb, Princeton, ¹¹Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: There is a substantial unmet need for effective, well-tolerated therapies for patients with SLE. Deucravacitinib is an oral, selective tyrosine kinase 2 (TYK2) inhibitor…
Abstract Number: LB11 • ACR Convergence 2025
Efficacy and Safety of Telitacicept in Patients with Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Study
Dong Xu¹, Shangzhu Zhang¹, Lin Qiao¹, Li Zhang¹, Wenxiang Wang², Lin Li², Binghua Xiao², Jing Zhang², Qing Zuraw³, Jianmin Fang² and Xiaofeng Zeng¹, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China (People's Republic), ²RemeGen Co., Ltd., Rheumatology, Yantai, China (People's Republic), ³Vor Biopharma Inc., Boston
Background/Purpose: Sjögren's disease (SjD) is a chronic autoimmune disease whose pathogenesis is associated with aberrant activation of B-lymphocytes. Telitacicept, a novel fusion protein, dually targets and…
Abstract Number: LB14 • ACR Convergence 2025
Promising Early Outcomes With BMS-986353, a CD19-directed Chimeric Antigen Receptor T Cell Therapy in Severe Refractory Idiopathic Inflammatory Myopathies: Safety and Efficacy Findings From the Ongoing Phase 1 Trial
Rohit Aggarwal¹, David Korman², Margrit Wiesendanger³, Vikas Majithia⁴, Ellen De Langhe⁵, Marc Schmalzing⁶, Melissa Griffith⁷, Philipp Koehler⁸, Joanna Schiller⁸, Dimitrios Mougiakakos⁹, Mohamad Cherry¹⁰, Richard Nash¹¹, Jacques Azzi¹², Ernesto Ayala⁴, Peter Vandenberghe⁵, Max Topp⁶, Jonathan Gutman⁷, Eugen Feist¹³, Alisha Desai¹⁴, Alexis Melton¹⁴, Alice Wozniak¹⁴, San-San Ou¹⁴, Melissa Harnois¹⁴, Jerill Thorpe¹⁴, Praneeth Jarugula¹⁴, Takafumi Ide¹⁴, Ashley Koegel¹⁴ and Neil Kramer¹⁵, ¹University of Pittsburgh, Pittsburgh, Pennsylvania, ²Mountain Rheumatology, HCA HealthONE, Denver, Colorado, ³Icahn School of Medicine at Mount Sinai, New York, New York, ⁴Mayo Clinic Hospital, Jacksonville, Florida, ⁵University Hospitals Leuven, Leuven, Belgium, ⁶University Hospital Würzburg, Würzburg, Germany, ⁷University of Colorado Anschutz Medical Campus, Aurora, Colorado, ⁸University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Division of Clinical Immunology and Center for Integrated Oncology (CIO) Aachen Bonn Cologne Duesseldorf, Cologne, Germany, ⁹University Hospital Magdeburg, Magdeburg, Germany, ¹⁰Atlantic Health System, Morristown, New Jersey, ¹¹HealthOne Cares and Colorado Blood Cancer Institute, Denver, Colorado, ¹²Icahn School of Medicine at Mount Sinai Hospital, New York, New York, ¹³Helios Vogelsang-Gommern Specialist Clinic, Gommern, Germany, ¹⁴Bristol Myers Squibb, Princeton, New Jersey, ¹⁵Overlook Medical Center and Atlantic Medical Group, Atlantic Health System, Morristown, New Jersey
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are systemic autoimmune diseases affecting muscles, skin, lungs, joints, and several other organs; many patients are refractory to available therapy,…
Abstract Number: 1258 • ACR Convergence 2025
Upadacitinib in the treatment of Rheumatoid Arthritis – Interstitial Lung Disease. National multicenter study of 25 patients in clinical practice.
Ana Serrano-Combarro¹, Belén Atienza-mateo², Leticia del Olmo Perez³, Sara García-Perez⁴, Guillermo Gonzalez Mozo de Rosales⁵, Jose Rosas Gómez de Salazar⁶, ana Urruticoechea-Arana⁷, Andrea García-Valle⁸, Jesús Loarce⁹, Paula García-Escudero¹⁰, Bryan Josué Flores Robles¹¹, Rafael B. Melero-González¹², Alicia Garcia¹³, Maria Martín López¹⁴, Patricia López Viejo¹⁵, Maria Jose Perez Gaan¹⁶, Nuria Vegas Revenga¹⁷, Angel Garcia-Aparicio¹⁸, M.Pilar Bernabeu Gonzalvez¹⁹, Juan Moreno Morales²⁰ and Ricardo Blanco²¹, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, PALMA DE MALLORCA/BALEARES, Spain, ³HGU Nuestra Señora del Prado, Talavera de la Reina, Talavera de la Reina, Spain, ⁴Complejo Hospitalario de Vigo, Vigo, Spain, ⁵Basurto University Hospital, Bilbao, Spain, ⁶Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ⁷Rheumatology Division. Hospital Universitario Son Espases, Palma de Mallorca, Spain, ⁸Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, ⁹Ramón y Cajal University Hospital, Madrid, Spain, ¹⁰Hospital Universitario Álava, Bilbao, Spain, ¹¹Hospital San Pedro, Logroño, Spain, ¹²COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ¹³Rheumatologist, La Laguna, Spain, ¹⁴Hospital ¹² de Octubre, Madrid, Spain, ¹⁵Hospital Severo Ochoa (Leganés), Leganes, Spain, ¹⁶Hospital Universitario Virgen de las Nieves, Granada, Spain, ¹⁷Galdakao- Usansolo University Hospital, Galdakao, Spain, ¹⁸Hospital Universitario de Toledo, Toledo, Spain, ¹⁹Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ²⁰Hospital Universitario Santa Lucia Cartagena, Cartagena, Spain, ²¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and rituximab are usually the recommended drugs. JAK inhibitors (JAKi)…
Abstract Number: 2267 • ACR Convergence 2025
Impact of Baseline Cardiovascular Risk Factors Comorbidities on an Adalimumab Biosimilar Efficacy, Quality of Life and Safety In Patients with Patients with Moderately to Severely Active Rheumatoid Arthritis: Results from the AURIEL-RA study
Chris Edwards¹, Janet Pope², Joelle Monnet³ and Maria Romanova Michailidi⁴, ¹University Hospital Southampton, Southampton, United Kingdom, ²University of Western Ontario, London, ON, Canada, ³Fresenius Kabi SwissBioSim, Eysins, Switzerland, ⁴University of Geneva, Eysins, Switzerland
Background/Purpose: RA has been associated with an increase risk of cardiovascular morbidity and mortality1. The present analysis was performed to assess the efficacy (on ACR…
Abstract Number: 1944 • ACR Convergence 2025
Musculoskeletal Ultrasound Clinic Referral Patterns and Joint Findings in a Tertiary Care Center amongst Patients with Elevated BMI and Inflammatory Arthritis
Anna Lichtiger¹, Ying Jin², Caroline Rourke¹, Kiera Brennan³, Hillary Weisleder⁴, Melissa Fazzari⁵ and Melissa Band⁶, ¹Montefiore Medical Center, The Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ⁴Montefiore Einstein, New York, NY, ⁵Department of Epidemiology & Population Health, Albert Einstein College of Medicine,, Bronx, NY, ⁶Montefiore Medical Center, New York, NY
Background/Purpose: Musculoskeletal ultrasound (MSUS) has been well known to aid in both early diagnosis and monitoring of inflammatory arthritis. Patients with an elevated BMI have…
Abstract Number: 1772 • ACR Convergence 2025
Correlation between Soluble Checkpoint Molecules and Disease Activity in Autoimmune Diseases
Kosaku Murakami¹, Akiko Yoshida², Hitoshi Uga³, Shuji Sumitomo⁴, Koichiro Ohmura⁵, Ryosuke Hiwa⁶, Tomohiro Kozuki⁷, Mao Kuroishi³, Chihiro Suminaka³, Mirei Shirakashi⁶, Hideaki Tsuji⁸, Shuji Akizuki⁶, Ran Nakashima⁶, Hajime Yoshifuji⁶, Akira Onishi⁹, Masao Tanaka⁹, Akio Morinobu¹⁰, Kenji Chamoto⁷ and Tasuku Honjo⁷, ¹Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ²Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Central Research Laboratories, Sysmex corporation, Kobe, Hyogo, Japan, ⁴Kobe City Medical Center General Hospital, Kobe city, Hyogo, Japan, ⁵Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan, ⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ⁷Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ⁸Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁹Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ¹⁰Kyoto University, Kyoto, Kyoto, Japan
Background/Purpose: Soluble checkpoint molecules (sCM) may be involved in the pathophysiology of autoimmune diseases by inhibiting the suppressive signals of immune cell activation through binding…
Abstract Number: 1633 • ACR Convergence 2025
Social Determinants of Health and Adverse Perinatal Outcomes in Women with Rheumatic Diseases
Andres M. Ortiz-Rios¹, Fany Rocio Arevalo-Nieto¹, Braulio R. Avalos-Garcia¹, Mara Alejandra Ponce-Santillan¹, Maria Eugenia Corral-Trujillo², Tania Sarahi Ayala-Garcia¹, Dunja Athalia Perez-Garfias¹, David Alejandro Ramirez-Cantu¹, Leonardo Uriel Tapia-Aguayo¹, Jesus Mario Ortiz-Palafox³, Eva Abigaid Galindo-Calvillo¹, Emmanuel Dominguez-Chapa⁴, Lorena Perez-Barbosa¹, Dionicio A. Galarza-Delgado⁵ and Cassandra Michele Skinner-Taylor¹, ¹Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterey, Nuevo Leon, Mexico, ⁴Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁵Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Social determinants of health (SDH) are the conditions in which individuals are born, grow, live and work. These factors (education, socioeconomic status, access to…
Abstract Number: 1496 • ACR Convergence 2025
Demyelinating Syndromes in Systemic Lupus Erythematosus: A 23-Year Retrospective Analysis of Clinical Features and Treatment Outcomes from a Tertiary Care Center
Manikandan Gopal¹, Ashish Jacob Mathew² and john mathew³, ¹christian medical college, Vellore, India, ²Christian Medical College, Vellore, Tamil Nadu, India, ³Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India
Background/Purpose: Systemic Lupus Erythematosus (SLE) with acute myelitis or optic neuritis is rare and causes significant morbidity. Data on these conditions remain limited. This study…
Abstract Number: 1339 • ACR Convergence 2025
Inflammatory Rheumatic Diseases in IDH-mutated Myeloid Neoplasms: Clinical Spectrum and Response to IDH Inhibitors
Romain Stammler¹, Peter Chen², Orianne Debeaupuis², Lin Pierre Zhao¹, Mirabelle Ruyer Thompson¹, Eve Zakine¹, Julien Rossignol¹, Lauriane Goldwirt¹, Thibault Comont³, Mael Heiblig⁴, Lionel Ades¹, Marie Sebert¹, Jean-sébastien Allain⁵, Julien Campagne⁶, Marie Anne Couturier⁷, Marina Cumin⁸, Marie Caroline Dalmas⁹, Guillaume Denis¹⁰, Cecile Devloo¹¹, Adrien De Voeght¹², Louis Drevon¹, Pierre Duffau¹³, Sophie georgin-Lavialle¹⁴, Delphine Gobert¹, Noemie Abisror¹⁵, Olivier Kosmider¹⁶, Fréderic Rieux-Laucat², Estibaliz LAZARO¹⁷, Jean Guillaume Lopez¹⁸, Alexandre Maria¹⁹, Wladimir Mauhin²⁰, Julie Merindol²¹, Claire Merlot²², Tristan Mirault¹, Laurent Pascal²³, François Perrin²⁴, Emmanuel Raffoux¹, Ramy Rahme²⁵, Damien Roos-Weil¹, Benjamin Terrier²⁶, Benjamin Torreau²⁷, Olivier Fain¹, Pierre Fenaux¹, Pierre Hirsch¹, Vincent Jachiet¹, Jerome Hadjadj¹ and Arsène Mekinian²⁸, ¹Assistance Publique des Hôpitaux de Paris, Paris, France, ²Imagine Institute, Paris, France, ³Centre Hospitalier Universitaire Toulouse Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France, ⁴Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, ⁵Scorff-Lorient Hospital, Lorient, France, ⁶Hospital Robert Schuman, Metz, France, ⁷Centre Hospitalier Régional et Universitaire de Brest, Brest, France, ⁸Centre hospitalier de Libourne, Libourne, France, ⁹Strasbourg University Hospital Center, Strasbourg, France, ¹⁰Centre Hospitalier Rochefort, Rochefort, France, ¹¹Centre hospitalier de Dieppe, Dieppe, France, ¹²CHU of Liège, Liège, Belgium, ¹³Groupe Hospitalier Saint-André, Bordeaux, France, ¹⁴Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ¹⁵Internal Medicine, CHU Saint-Antoine,, Paris, France, ¹⁶AP-HP, Hopital Cochin, Institut Cochin, CNRS UMR⁸¹⁰⁴, INSERM U¹⁰¹⁶ Université Paris Cité Paris France., PARIS, France, ¹⁷Bordeaux University Hospital, Pessac, France, ¹⁸Dupuytren University Hospital, Limoges, France, ¹⁹Saint-Eloi Hospital, Montpellier, France, ²⁰Croix Saint Simon Hospital, Paris, France, ²¹University Hospital of Nice, Nice, France, ²²Centre hospitaliser d’Orléans, Orléans, France, ²³Hôpital Saint-Vincent de Paul, Lille, France, ²⁴Centre Hospitalier de Saint-Nazaire, Saint Nazaire, France, ²⁵Assistance Publique des Hôpitaux de Paris, Bobigny, France, ²⁶Cochin Hospital, Paris, France, ²⁷Internal Medicine and Immunology, CHU Tours, Tours, France, ²⁸Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France
Background/Purpose: Clonal hematopoiesis has emerged as a key contributor to systemic inflammation, bridging hematologic and immune-mediated inflammatory disorders (IMIDs). Isocitrate dehydrogenase 1 and 2 (IDH1/2)…
Abstract Number: 1161 • ACR Convergence 2025
Comparative efficacy, safety and tolerability of antifibrotic therapies across systemic autoimmune diseases
Javier Narváez¹, Orfa Barrios², Pol Maymó-Paituvi³, JUAN JOSE ALEGRE SANCHO⁴, Ivan Castellví⁵, Vanesa Vicens Zygmunt⁶, Guadalupe Bermudo⁷, Laia De Daniel Bisbe³, Martí Aguilar-Coll⁸, Montserrat Roig Kim³, Joan Miquel Nolla³ and Maria Molina-Molina⁷, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology. Hospital Nacional Arzobispo Loayza, Lima, Peru, ³Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁴Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ⁵Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, barcelona, Spain, ⁶Interstitial Lung Disease Unit. Department of Pneumology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷Interstitial Lung Disease Unit. Department of Pneumology. Hospital Universitario de Bellvitge., Barcelona, Spain, ⁸Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To evaluate the efficacy, safety, and tolerability of the antifibrotic agents nintedanib and pirfenidone in the treatment of interstitial lung disease (ILD) associated with…
Abstract Number: 1023 • ACR Convergence 2025
Comparative Analysis of Oral Health and Dental Care in Patients With Immune-Mediated and Non-Immune-Mediated Rheumatic Diseases
Margarita Isabel Alarcon-Jarquin¹, Fernanda M. Garcia-Garcia², Vanessa L. Lopez-Flores¹, Aranxa Galindo-Bandt³, Mario A. Arellano-Alvarez³, Aleydis Gonzalez-Melendez³, Gabriel Figueroa-Parra³, Dionicio A. Galarza-Delgado² and Janett C. Riega-Torres⁴, ¹Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Oral health impairment is common in patients with immune-mediated rheumatic diseases (IMRDs) due to chronic inflammation and immune dysregulation. These complications can worsen systemic…
Abstract Number: 0947 • ACR Convergence 2025
Mechanisms of anti-NMDAR antibody-mediated neuronal pathology and mitigation by angiotensin II signaling inhibition
Kaitlin Carroll¹, Mark Mizrachi¹, Sean Simmons², Bahtiyar Toz¹, Czeslawa Kowal³, Nazila Tehrani¹, Aida Zarfeshani¹, Nina Kello¹, Lara El Khoury⁴, Jeffrey Wingard¹, Rachel Weissman-Tsukamoto³, Joshua Levin², Bruce Volpe³ and Betty Diamond⁵, ¹Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Manhasset, NY, ²Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, ³Feinstein Institute of Molecular Medicine, Manhasset, NY, ⁴Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ⁵The Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Cognitive impairment is a frequent manifestation of neuropsychiatric systemic lupus erythematosus, present in up to 80% of patients and leading to a diminished quality…
Abstract Number: 0905 • ACR Convergence 2025
Development and Characterization of IAR130, a 2+1 Format, CD19 and BCMA Dual Targeting T Cell Engager for Autoimmune Diseases
Jinyang Li, Xiu Han, Yi Wang, Yiyi Li, Zhaoru Ma, Yang Li, Zhimin Zhang, Liu Li, Meng Ni, Jiangkun Bi, Xing Yang, Yao Xiong, Shuaixiang Zhou and Huizhong Xiong, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)
Background/Purpose: Immune reset, achieved through profound and sustained depletion of B cells and/or plasma cells, has demonstrated significant clinical efficacy in patients with severe and…

1
2
3
…
101
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].